Precigen director receives new stock and option awards

PRECIGEN, INC. director Nancy H. Agee received equity-based compensation on March 10, 2026.

Rhea-AI Filing Summary

PRECIGEN, INC. director Nancy H. Agee received equity-based compensation on March 10, 2026. She was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027. She also received an option to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, she was issued 16,096 shares of common stock in lieu of an annual cash retainer of $56,500. Following these awards, her directly held common stock position reported in this filing is 233,937 shares.

Insider Trade Summary

Grant/Award: 92,781 shares

Grant/Award 3 txns

Insider AGEE NANCY H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	35,612	$0.00	$0.00
Grant/Award	Option to Purchase Common Stock (Right to Buy)	41,073	$0.00	$0.00
Grant/Award	Common Stock	16,096	$3.51	$56K

Holdings After Transaction: Restricted Stock Units — 35,612 contracts (Direct); Option to Purchase Common Stock (Right to Buy) — 41,073 contracts (Direct); Common Stock — 233,937 shares (Direct)

Footnotes (3)

1. F1. The shares were issued to the reporting person in lieu of an annual retainer of $56,500.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
3. F3. The RSUs vest in full on March 10, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Precigen (PGEN) report for Nancy H. Agee?

Precigen (PGEN) reported that director Nancy H. Agee received stock-based compensation on March 10, 2026. She was granted restricted stock units, stock options, and common shares issued in lieu of a cash retainer as part of her board compensation package.

How many restricted stock units did Nancy H. Agee receive from Precigen (PGEN)?

Nancy H. Agee received 35,612 restricted stock units from Precigen (PGEN). Each RSU represents a contingent right to receive one share of Precigen common stock, and the entire RSU grant is scheduled to vest in full on March 10, 2027.

What are the terms of Nancy H. Agee’s stock options from Precigen (PGEN)?

Nancy H. Agee received options to purchase 41,073 shares of Precigen (PGEN) common stock. These options have an exercise price of $3.51 per share, were granted on March 10, 2026, and are scheduled to expire on March 10, 2036.

Why did Precigen (PGEN) issue common shares to Nancy H. Agee?

Precigen (PGEN) issued 16,096 shares of common stock to Nancy H. Agee in lieu of an annual board retainer of $56,500. This converts her cash director compensation into equity, further aligning her interests with those of the company’s shareholders.

When do Nancy H. Agee’s restricted stock units from Precigen (PGEN) vest?

Nancy H. Agee’s restricted stock units from Precigen (PGEN) vest in full on March 10, 2027. After vesting, each RSU is expected to settle into one share of Precigen common stock, increasing her directly owned share count if she continues to hold them.

How many Precigen (PGEN) common shares does Nancy H. Agee hold after these grants?

After the March 10, 2026 grants, Nancy H. Agee’s directly held Precigen (PGEN) common stock position reported in the filing is 233,937 shares. This figure reflects her updated ownership following the award of 16,096 common shares in lieu of her annual retainer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGEE NANCY H

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		16,096	A	$3.51(1)	233,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/10/2026		A		35,612		(3)	(3)	Common Stock	35,612	$0	35,612	D
Option to Purchase Common Stock (Right to Buy)	$3.51	03/10/2026		A		41,073		03/10/2026	03/10/2036	Common Stock	41,073	$0	41,073	D

Explanation of Responses:

1. The shares were issued to the reporting person in lieu of an annual retainer of $56,500.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

3. The RSUs vest in full on March 10, 2027.

	/s/ Nancy H. Agee, by Donald P. Lehr, as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.